Finance

Eyeing functional cure, Excision raises $60M to advance CRISPR-based HIV program into Phase I/II 

With primate data in hand for its CRISPR-based HIV therapy, Excision raised a $60 million round to advance into the clinic this year. 

Antiretroviral